Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Nature Reviews. Drug Discovery
|
February 27, 2025
Clinical development success rates for durable cell and gene therapies
Sharon Phares, Katie Phillip, Mark Trusheim
Data in Brief
|
February 24, 2022
Data for modelling US projections of product approvals, patients treated, and product revenues for durable cell and gene therapies
Colin M Young, Mark Trusheim, Casey Quinn
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 15, 2019
Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System
Casey Quinn, Colin Young, Jonathan Thomas, et al.
International Journal of Technology Assessment in Health Care
|
April 11, 2018
DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK
Joost de Folter, Mark Trusheim, Pall Jonsson, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 26, 2023
Payer and Developer perspectives on alternative payment models
Renita Moradian, Tsega Meshesha, Mark Trusheim, et al.
The New England Journal of Medicine
|
January 30, 2020
Understanding the Rewards of Successful Drug Development - Thinking Inside the Box
Dhruv Khullar, Jennifer A Ohn, Mark Trusheim, et al.
Journal of Comparative Effectiveness Research
|
November 14, 2024
Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States
Sharon Phares, Mark Trusheim, Sarah K Emond, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
December 29, 2022
Medicaid best price reforms to enable innovative payment models for cell and gene therapies
Casey Quinn, Michael Ciarametaro, Brian Sils, et al.
Nature Reviews. Drug Discovery
|
September 13, 2016
Investigating investment in biopharmaceutical R&D
Percy H Carter, Ernst R Berndt, Joseph A DiMasi, et al.
Drug Discovery Today
|
June 3, 2024
Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity
Marcelien H E Callenbach, Wim G Goettsch, Aukje K Mantel-Teeuwisse, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Nature Reviews. Drug Discovery
|
February 27, 2025
Clinical development success rates for durable cell and gene therapies
Sharon Phares, Katie Phillip, Mark Trusheim
Data in Brief
|
February 24, 2022
Data for modelling US projections of product approvals, patients treated, and product revenues for durable cell and gene therapies
Colin M Young, Mark Trusheim, Casey Quinn
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 15, 2019
Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System
Casey Quinn, Colin Young, Jonathan Thomas, et al.
International Journal of Technology Assessment in Health Care
|
April 11, 2018
DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK
Joost de Folter, Mark Trusheim, Pall Jonsson, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 26, 2023
Payer and Developer perspectives on alternative payment models
Renita Moradian, Tsega Meshesha, Mark Trusheim, et al.
The New England Journal of Medicine
|
January 30, 2020
Understanding the Rewards of Successful Drug Development - Thinking Inside the Box
Dhruv Khullar, Jennifer A Ohn, Mark Trusheim, et al.
Journal of Comparative Effectiveness Research
|
November 14, 2024
Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States
Sharon Phares, Mark Trusheim, Sarah K Emond, et al.
Expert Review of Pharmacoeconomics & Outcomes Research
|
December 29, 2022
Medicaid best price reforms to enable innovative payment models for cell and gene therapies
Casey Quinn, Michael Ciarametaro, Brian Sils, et al.
Nature Reviews. Drug Discovery
|
September 13, 2016
Investigating investment in biopharmaceutical R&D
Percy H Carter, Ernst R Berndt, Joseph A DiMasi, et al.
Drug Discovery Today
|
June 3, 2024
Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity
Marcelien H E Callenbach, Wim G Goettsch, Aukje K Mantel-Teeuwisse, et al.
Page
of 2